Cartography raises $67 million in Series B financing led by Pfizer Ventures to advance its oncology pipeline, including the lead program CBI-1214 into Phase 1 trials.

Oct 02, 2025•9 days ago

Amount Raised

$67 Million

Round Type

series b

San FranciscoBiotechnology

Investors

GaingelsArtis VenturesAme Cloud VenturesCatalio Capital ManagementWing Venture Capital8 VcAndreessen Horowitz (A16z) Bio + HealthLotte Holdings CvcGlobal Bio Access FundFinchley H.V.Amgen VenturesLg CorpPfizer Ventures

Description

Cartography Biosciences, Inc. has secured $67 million in Series B financing to support its oncology programs. The funding will help advance its lead program, CBI-1214, into the clinic. Pfizer Ventures led the round, joined by other investors like LG Corp and Amgen Ventures

Company Information

Company

Cartography Biosciences

Location

San Francisco, California, United States

About

Cartography Biosciences is building a differentiated oncology pipeline of antibody-based therapies designed to target tumors more precisely than existing therapeutics. Cartography’s ATLAS and SUMMIT drug discovery platforms are powered by an industry-leading, fully integrated dataset spanning hundreds of thousands of cell states across the healthy body and large-scale profiling of individual cells from patient tumors. By leveraging petabytes of proprietary data, along with insights from machine learning and AI, Cartography is identifying and developing therapeutics against highly specific targets and target pairs to build a pipeline of molecules with the greatest patient impact. Cartography’s lead program in preclinical development, CBI-1214, is a T-cell engager being advanced for CRC.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends